Operational Costs Compared: SG&A Analysis of Alkermes plc and Iovance Biotherapeutics, Inc.

A Decade of SG&A Trends: Alkermes plc vs. Iovance Biotherapeutics, Inc.

In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Alkermes plc and Iovance Biotherapeutics, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting its strategic investments in growth and market expansion. In contrast, Iovance Biotherapeutics, Inc. experienced a staggering increase of over 1,000% in the same period, indicative of its aggressive scaling and development efforts.

Key Insights

• Alkermes plc: Starting at 200 million in 2014, their SG&A expenses peaked at nearly 690 million by 2023, showcasing a steady upward trajectory.
• Iovance Biotherapeutics, Inc.: From a modest 9 million in 2014, their expenses soared to over 106 million in 2023, highlighting rapid growth.

These trends underscore the dynamic nature of the biotech industry, where strategic spending is crucial for innovation and market leadership.